By the Top Tier Newswire AI Desk · August 4, 2026 at 5:54 AM ET · reviewed against 4 wire stories
CAREDX INC (CDNA) is up +9.47% in the latest session. Our newswire has captured 4 stories on CDNA across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
CDNA stock rose 9.47 percent to $47.85 in morning trading on Monday, marking a new 52-week high. The surge followed a strong second-quarter earnings report that beat estimates and a raised 2026 guidance. The stock’s performance was also supported by a recent executive appointment and positive momentum in the healthcare sector.
What Happened
CareDx reported adjusted earnings per share of $0.37 for the second quarter, exceeding the estimated $0.23. Revenue came in at $131.948 million, surpassing the projected $114.044 million. The company also raised its 2026 guidance, signaling confidence in its growth trajectory. Additionally, CareDx announced the appointment of James McNally as Executive Advisor and awarded him 15,822 restricted stock units under its equity incentive plan. The RSUs will vest in two equal tranches through 2027. These developments have fueled investor optimism, particularly in the context of broader market enthusiasm for healthcare and AI-related stocks.
What The Data Shows
The stock has traded between $11.26 and $45.00 over the past 52 weeks. With a market cap of $2.3 billion, CareDx is valued at a P/E ratio of 20.6, supported by a revenue growth of 34.4 percent trailing twelve months and a net margin of 24.2 percent. The stock has a beta of 2.43, indicating higher volatility compared to the market. Recent insider transactions show 8 sales totaling $8.2 million over the last 90 days, with the most recent filing on July 17.
What To Watch
Investors should monitor CareDx’s upcoming earnings reports and any further updates on its strategic initiatives. The company’s guidance and leadership developments will be key factors in sustaining the current momentum.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Snowflake and CareDx received favorable reviews from Wall Street firms, following better-than-expected second-quarter prints and bullish momentum across AI products, respectively.
7d agoMarketChameleonBULLISH 56General
CareDx’s New Executive Advisor Receives 15,822 RSU Award—What This Could Mean for Stakeholders
August 3, 2026
CareDx has granted 15,822 restricted stock units to newly appointed Executive Advisor James McNally under its Inducement Equity Incentive Plan. This article explores the structure and implications of the award, and what the staggered vesting might signal about the company's strategy and outlook.
7d agoSeeking AlphaBULLISH 73Earnings
CareDx climbs another 9% after guidance raise, sets new 52-week high
CareDx (CDNA) stock hits new highs after Q2 earnings beat and raised 2026 guidance.
7d agoMarketChameleonBULLISH 56General
CareDx Grants Nearly 16,000 RSUs to Executive Advisor as Part of Strategic Leadership Expansion
August 3, 2026
CareDx has granted 15,822 restricted stock units to its newly appointed Executive Advisor, James McNally, highlighting a leadership-focused growth move. The RSUs will vest in two equal tranches through 2027 and were approved under inducement provisions per Nasdaq requirements.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →